Abstract: Mansonone G (MG), a plant-derived compound isolated from the heartwood of *Mansonia gagei*, possesses a potent antitumor effect on several kinds of malignancy. However, its poor solubility limits the use for practical applications. Beta-cyclodextrin (βCD), a cyclic oligosaccharide composed of seven (1→4)-linked α-D-glucopyranose units, is capable of encapsulating a variety of poorly soluble compounds into its hydrophobic interior. In this work, we aimed to enhance the water solubility and the anticancer activity of MG by complexation with βCD and its derivatives (2,6-di-O-methyl-βCD (DMβCD) and hydroxypropyl-βCD). The 90-ns molecular dynamics simulations and MM/GBSA-based binding free energy results suggested that DMβCD was the most preferential host molecule for MG inclusion complexation. The inclusion complex formation between MG and βCD(s) was confirmed by DSC and SEM techniques. Notably, the MG/βCDs inclusion complexes exerted significantly higher cytotoxic effect (~2–7 fold) on A549 lung cancer cells than the uncomplexed MG.

Keywords: beta-cyclodextrins; inclusion complex; mansonone G; molecular dynamics simulation; lung cancer

1. Introduction

Cancer is a major public health issue and is ranked as the second leading cause of mortality worldwide following cardiovascular disease [1]. Several plant-derived compounds containing naphthoquinone (NQ) moiety such as beta-lapachone, plumbagin, and shikonin have been reported to exert a superior antiproliferative activity [2–4]. Mansonones, group of ortho-NQ-containing compounds, are the major bioactive constituents of the diverse plant genera, including *Mansonia*, *Hibiscus*, and *Thespesia* [5]. Previous studies revealed that mansonones D, E, F, and H possess the anticancer effect on
several kinds of solid tumors [6–8]. In addition, the novel derivative of mansonone F exhibited 20-fold stronger DNA topoisomerase II inhibitory activity than the chemotherapeutic drug etoposide [9].

Among the eight different mansonones (mansonones A–H) [10], mansonone G (MG, Figure 1A) is the major product isolated from the heartwood of Mansonia gagei Drumm., Sterculiaceae family found in Thailand [11]. Many lines of evidence have shown that MG exhibits a potent anticarcinogenic effect on various types of malignancies, e.g., ovarian (A278, IC50 of 10.2 μM), colorectal (HCT116, IC50 of 63.4 μM), liver (HepG2, IC50 of 36.3 μM and Huh-7, IC50 of 25.9 μM), breast (MCF-7, IC50 of 23.0 μM), and cervical (HeLa, IC50 of 18.8 μM) cancer cell lines [5,12,13], and it has been documented to significantly inhibit the activity of P-glycoprotein efflux pump [5]. Recently, the butoxy MG has shown to potentially induce cell apoptosis in human lung cancer cell lines A549 and H1975 by inhibiting STAT3 and Akt signaling pathways [14]. Even though MG could serve as a promising anticancer agent, its poor water solubility (1.7 mg/L at 30 °C) leads to a limited use for pharmaceutical and medicinal applications.

Cyclodextrin (CD), a naturally occurring cyclic oligosaccharide produced by CD glucanotransferase (CGTase)-catalyzed starch degradation [15], has a unique structure representing a hydrophobic inner cavity and a hydrophilic outer surface. Consequently, CD can potentially enhance the solubility, stability, and pharmacological properties of many lipophilic guest molecules [16,17] through the formation of an inclusion complex driven mainly by van der Waals (vdW) interactions [18]. The common types of CD are alpha (α), beta (β), and gamma (γ) CDs formed by six, seven, and eight α-D-glucopyranose units, respectively. Among the three CDs, βCD (Figure 1B) is the most commonly used in many pharmaceutical purposes due to its low price, easy synthetic access, and structural orientation suitable for inclusion complex generation [19,20]. However, the low water solubility (18.5 mg/mL at 25 °C) and nephrotoxicity of βCD limit its use for practical applications [21].

In recent years, the use of βCD derivatives (e.g., methylated (M) and 2-hydroxypropylated (HP) βCDs) for host-guest encapsulation has gained much attention in an attempt to improve the water solubility and to reduce the limitations of natural βCD. The MβCD (e.g., 2,6-di-O-methyl-βCD; DMβCD) and the HPβCD derivatives exhibit higher aqueous solubility and lower toxicity than the unmodified βCD [21–23]. Several experimental and theoretical reports (both classical molecular dynamics (MD) and density functional theory (DFT)) have demonstrated that the water solubility, chemical stability, and anticancer activity of poorly soluble molecules are significantly improved by complexation with DMβCD and HPβCD derivatives [24–28]. However, the information on the inclusion complexes of MG with βCDs has never been previously reported. Therefore, the present study aimed to enhance the physical and biological properties of MG using βCD and its derivatives (DMβCD and HPβCD) based on working hypothesis that the anticancer activity of MG may be positively affected by βCDs. The all-atom MD simulations and binding free energy calculations were firstly applied (i) to search for the suitable βCD encapsulating molecule for MG and (ii) to investigate the atomistic insights into host-guest complexation and its underlying interactions. Subsequently, the phase solubility study between MG and βCDs was experimentally verified, and the physical and chemical characterization techniques were used to confirm the inclusion complex formation. Finally, the resulting MG/βCDs complexes were subjected to evaluate the antitumor activity toward A549 human lung cancer cell line in comparison to the MG alone.

2. Materials and Methods

2.1. Computational Details

The 3D structures of MG and all the investigated βCD analogs (βCD, DMβCD, 2HPβCD, 6HPβCD, and DHPβCD) were taken from previous studies [29–31]. It should be noted that (i) the hydroxyl group of MG is protonated (neutral form) based on NMR data from previous studies [11,32] and (ii) the commercially available HPβCD is a mixture of various degree of substitution (DS), while the models we built in this study were fully (DHPβCD; DS = 14) and partially (2HPβCD and 6HPβCD; DS = 7) substituted HPβCDs. The inclusion complexes were generated in Accelrys Discovery
Studio 2.5 (Accelrys Software Inc., San Diego, CA, USA) by docking protocols using CDOCKER module. The partial charges of MG molecule were created as per the standard procedures [33–35]. The Glycam-06 [36] and general AMBER force fields [37] were applied on βCDs and MG, respectively. Using a truncated octahedral box, the TIP3P water molecules were used to solvate around MG/βCDs complexes with a spacing distance of 15 Å. After that, the added water molecules were minimized using 1000 steps of steepest descent and continued by 3000 steps of conjugated gradient. Lastly, the whole model was optimized as per the same methods.

Under periodic boundary condition with a time step of 2 fs, each solvated inclusion complex was heated up from 10 K to 303 K for 60 ps, and followed by all-atom MD simulations (NPT ensemble, temperature of 303 K and pressure of 1 atm) using AMBER16 for 90 ns in triplicate. All chemical bonds involving hydrogen were constrained using the SHAKE algorithm [38]. The particle mesh Ewald method [39] was employed to treat charge-charge interactions with a cutoff of 12 Å. The molecular mechanics/generalized Born surface area (MM/GBSA)-based binding free energy (ΔG_{bind, MM/GBSA}) calculation [40] was used to estimate the binding affinity of all the studied inclusion complexes.

2.2. Experimental Part

2.2.1. Chemical Reagents

MG was extracted from Mansonia gagei Drumm according to the previous study [11]. βCD (MW 1134.98) was obtained from Acros Organics (Morris Plains, NJ, USA), whereas the Heptakis(2,6-di-O-methyl)-β-cyclodextrin (DMβCD; MW 1331.36), (2-Hydroxypropyl)-β-cyclodextrin (HPβCD; MW 1396; average DS is 0.5–1.3 unit of 2-hydroxypropyl group per glucose unit), dimethyl sulfoxide (DMSO), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, MO, USA).

2.2.2. Cell lines and Culture

A549 human lung cancer cell line was obtained from Dr. Apiwat Mutirangura (Chulalongkorn University, Thailand). A549 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS; Gibco), 100 U/mL penicillin, and 100 µg/mL streptomycin (Gibco) and were maintained at 37 °C in a humidified 5% CO2 atmosphere.

2.2.3. Phase Solubility Study and Evaluation of Thermodynamic Parameters

Phase solubility study was conducted by following the method of Higushi and Connors [41]. Briefly, an excess amount of MG was added to βCD(s) solutions (0–10 mM). The mixtures were shaken (250 rpm) at 30 °C, 37 °C, and 45 °C for 72 h. Subsequently, the suspensions were centrifuged at 12,000 rpm for 15 min. The amount of MG presenting in solution was measured by UV-Vis spectroscopy at 415 nm. The Equation (1) was used to calculate the apparent stability constant (Kc), where S0 is y-intercept.

\[
K_c = \frac{\text{Slope}}{S_0(1 - \text{slope})}
\]  

The Van’t Hoff plot based on Equation (2) [17] was used to identify the thermodynamic properties, including enthalpy (ΔH) and entropy (ΔS) changes of inclusion complexation, whilst the experimental Gibbs free energy (ΔG_{bind, exp}) was obtained from Equation (3).

\[
\ln K_c = -\frac{\Delta H}{RT} + \frac{\Delta S}{R}
\]

\[
\Delta G_{bind, exp} = \Delta H - T\Delta S
\]
2.2.4. Inclusion Complex Preparation

A 1:1 stoichiometric ratio of MG/βCD(s) inclusion complex was prepared by the freeze-drying method. Each accurately weighed compound (73.28 mg MG, 340.49 mg βCD, 399.41 mg DMβCD, and 418.80 mg HPβCD) was dissolved in deionized water (30 mL), then the mixture was magnetically stirred at room temperature for 24 h. After that, the suspension was centrifuged (12,000 rpm for 15 min) and filtered through a 0.45 µm filter. The obtained solution was then frozen overnight at −80 °C and subsequently lyophilized using LYO-LAB (Lyophilization Systems Inc., USA) for 3 days. In addition, a 1:1 molar ratio of MG and βCD(s) was physically mixed at room temperature to obtain the physical mixtures, which were used for comparison. The resulting freeze-dried powders and physical mixtures were stored in desiccator for further use.

2.2.5. Determination of Solubility

Excess quantity of pure MG and its inclusion complexes was added to 1 mL of deionized water. The mixture was continuously stirred at 30 °C for 24 h. Subsequently, the suspension was filtered through a 0.45 µm filter, and the solubility of MG was characterized by measuring the absorbance at a wavelength of 415 nm.

2.2.6. Inclusion Complex Characterization

Differential Scanning Calorimetry (DSC)

The thermal behavior of the MG, βCD, DMβCD, MG/βCD, and MG/DMβCD was characterized using NETZSCH DSC 204F1 Phoenix. Each solid sample (~1–2 mg) was heated from 25 °C to 300 °C in aluminum pans at a rate of 10 °C/min.

Scanning Electron Microscope (SEM)

The surface morphology of MG, βCD, DMβCD, the freeze-dried inclusion complexes, and the physical mixtures was analyzed using a Scanning Electron Microscope (JEOL JSM-IT500HR). Samples were coated with a thin layer of gold in vacuum before viewing under 300 times magnification. Observations were performed using an accelerating voltage of 10 kV.

2.2.7. Cytotoxicity of MG toward Lung Cancer Cells

Cell viability was evaluated using MTT assay. A549 cells were seeded into 96-well plates at a density of 3 × 10^3 cells/well. After overnight incubation, cells were treated with logarithmic concentrations (1, 3, 10, 30, and 100 μM) of MG, MG/βCD, MG/DMβCD, and MG/HPβCD for 48 h. Note that the amount of treated MG in free form and in complexes is equivalent. After that, MTT solution (5 mg/mL) was added to each well and then incubated at 37 °C for another 4 h. Subsequently, the culture medium was withdrawn and 150 μL of DMSO solution was added to dissolve formazan crystals. Finally, the absorbance was measured at 570 nm using UV-Vis spectrophotometer (Thermo Scientific, Vantaa, Finland). The half-maximal inhibitory concentration (IC_{50}) was calculated using GraphPad Prism 7 software.

2.2.8. Statistical Analysis

The quantitative data are expressed as mean ± standard error of mean (SEM) of three independent experiments. Differences between groups were determined using one-way analysis of variance (ANOVA) followed by a Newman-Keuls post hoc test. The p value of ≤0.05 was considered statistically significant.
3. Results and Discussion

From docking study, MG could form two possible inclusion complexes with βCDs through its aromatic ring (A-ring, form I) or quinone ring (Q-ring, form II) insertion into the hydrophobic cavity. However, after performing all-atom MD simulations for 90 ns in triplicate on both forms (altogether 30 independent simulations), only form I of MG/βCD, MG/DMβCD, and MG/2HPβCD is likely stable, whilst the dissociation of inclusion complex is detected in the form II of all systems as well as the form I of MG/6HPβCD and MG/DHPβCD. The latter finding is consistent well with previous study showing that the HP modification on βCD at C6-position (DS = 7) led to the dissociation of the encapsulated mansonones E and H from hydrophobic inner cavity [42]. Therefore, the MG/βCD, MG/DMβCD (DS = 14), and MG/2HPβCD (DS = 7) complexes in form I were further focused in this study.

3.1. Ligand Mobility Inside βCD’s Hydrophobic Cavity

The dynamics behavior of the encapsulated MG inside hydrophobic interior of βCD(s) along the simulation time was studied using the calculations of the distance between the center of mass (Cm) of each ring of MG (A-ring (black) and Q-ring (grey)) and the Cm of βCD without taking into account the functional substituents. The obtained results are shown in Figure 2A, whereas the representative binding mode of MG/βCD(s) taken from the final MD snapshot is depicted in Figure 2B. The horizontal grey box ranging from −3.95 Å to 3.95 Å (~7.9 Å) represents the positions of the primary (narrow) and secondary (wider) rims of native βCD, respectively [43]. In the case of MG/βCD and MG/2HPβCD systems, MG stably positions nearby the wider rim of βCD(s) and preferentially inserts the A-ring inside the hydrophobic inner cavity. By considering the MG/DMβCD models, MG rapidly moves toward the narrow rim of DMβCD after the heating step and subsequently positions in this orientation until the end of the simulations.
3.2. βCDs Conformations Upon MG Binding

The βCD(s) conformational changes upon MG encapsulation were investigated by calculating (i) the distance of the secondary hydroxyl groups on the wider rim of βCDs (O3(n)–O2(n+1), dO3-2), corresponding to a possibility of intramolecular hydrogen bond (H-bond) generation (dO3-2 of ≤3.5 Å), and (ii) the distance of glycosidic oxygen atoms (O4(n)–O4(n+1), dO4-4) (Figure 3A, left). Afterward, the Equation (4) was used to transform the distributions of these two parameters into the free energy value, F(x,y):

\[
F(x,y) = -k_B T \log[P(x,y)]
\]  (4)

where \( k_B \) is the Boltzmann constant, \( T \) is the temperature (303 K), and \( P(x,y) \) is the probability of dO3-2 (x) and dO4-4 (y). The potential energy surface (PES) is shown in Figure 3A, in which the M1 area is the most stable form of the βCD(s), whilst the M2 region represents the rotation of the α-D-glucopyranose units.

As compared to the unbound form of βCDs exhibiting three local minima areas: M1 (dO3-2 of ~3.0–4.5 Å and dO4-4 of ~4.3–4.7 Å), M2 (dO3-2 of ~5 Å and dO4-4 of ~4.5–5.2 Å), and M3 (dO3-2 of ~5 Å and dO4-4 of ~6 Å) [30], the molecular encapsulation of MG toward DMβCD and 2HPβCD dramatically induces the stable conformation of βCD(s) by enhancing the formation of intramolecular H-bonds on the wider rim, as evidenced by the obviously increased population in M1 region (dO3-2 of ~2.5–4.5 Å and dO4-4 of ~4.1–4.9 Å, Figure 3A). In addition, the M3 region with both lengthened distances, which was only detected in the free form of βCDs, is completely disappeared in all MG-bound systems. These H-bond-operated conformational changes of βCD(s) upon the ligand binding correlate well with previously published research [44]. However, the distortion of glucopyranose units represented by M2 area is found in MG/βCD and MG/2HPβCD systems, but not in MG/DMβCD models, indicating that MG/DMβCD is the most stable complex, which is consistent with \( \Delta G_{bind, MM/GBSA} \) calculations (Table 1) as well as the experimental \( K_c \) and \( \Delta G_{bind, exp} \) values (Tables 2 and 3) as discussed later.
We further characterized the native contact points within 3 Å between MG and βCDs during the last 20-ns MD simulations. The obtained results (Figure 3B) reveal that MG/DMβCD inclusion complex displays the highest number of contacts per α-D-glucopyranose units (6.97 ± 0.62) followed by MG/2HPβCD (6.58 ± 0.78) and MG/βCD (6.06 ± 0.40) complexes, respectively, as clearly shown by the representative 3D contact structures (Figure 3B, top) demonstrating that MG/DMβCD exhibits the most compact feature. Altogether, the native-contact-driven structures consistently support the PES calculations.

![Figure 3](image-url)

**Figure 3.** (A) The distance parameters (dO₃-2 and dO₄₄) used for PES calculations (left) and the obtained results (right). (B) The representative native contact PDB structures shown in line mode (top) and the number of contacts between MG and α-D-glucopyranose units of βCDs (bottom). Data are expressed as mean ± SEM of three independent MD simulations.

### 3.3. Solvent Accessibility Toward Inclusion Complexes

The effect of water accessibility on MG/βCD(s) inclusion complex formation was characterized by solvent accessible surface area (SASA) calculations using MG as the atomic radii for solvent-exposed area. The entire SASA results are depicted in Figure 4A, whereas the average SASA values taken from the last 20-ns MD simulations are illustrated in Figure 4B.

Data in Figure 4A indicate that the SASAs of MG/βCD and MG/DMβCD systems are more stable than those of MG/2HPβCD complexes. In the case of MG/βCD, the SASAs fluctuate in the range of ~150–250 Å², whereas the SASAs of MG/DMβCD are relatively steady at ~150 Å² along the simulation times. By considering the MG/2HPβCD models, the SASA values considerably
fluctuate (~200–300 Å²) at 40–70 ns and subsequently decrease to ~150 Å² after 70 ns (except MD1). The average SASA values over the last 20 ns from three independent simulations in Figure 4B reveal that the complexation of MG with DMβCD significantly decreases the water accessibility toward the MG molecule inside hydrophobic inner cavity as compared to the MG/βCD and MG/2HPβCD (* p ≤ 0.05). These observations correlate well with previous study [45] demonstrating that the lowest solvent exposed inclusion complex displayed the highest binding affinity. However, the SASAs of MG/βCD and MG/2HPβCD are not significantly different, suggesting that DMβCD is the most preferred encapsulating agent for MG, which is in good correlation with MM/GBSA-based free energy calculations as discussed in the next section.

Figure 4. (A) SASA of MG/βCD, MG/DMβCD, and MG/2HPβCD for three different MD runs. (B) The average SASA over the last 20-ns MD simulations for each inclusion complex. Data are expressed as mean ± SEM (n = 3). n.s., not significantly different. * p ≤ 0.05.

3.4. Binding Free Energy of Inclusion Complexes

To estimate the binding affinity of the inclusion complexes, we applied MM/GBSA [46] calculation on each MG/βCD(s) using 300 snapshots extracted from the last 20-ns MD simulations. The average ΔG_{bind, MM/GBSA} and its energy components, vdW (ΔE_{vdW}) and electrostatic (ΔE_{ele}) energies, for MG/βCDs are summarized and compared in Table 1. As expected, due to the poor solubility of MG, the host-guest complexation in gas phase is driven predominantly by vdW interactions (~ -27 to -29 kcal/mol). Similarly, the summation of ΔG_{solv,non-polar} + ΔE_{vdW} energies (~ -30 to -32 kcal/mol) is much lower than the ΔG_{solv,polar} + ΔE_{ele} terms (~8 to 10 kcal/mol), indicating the vdW forces play a pivotal role in the formation of MG/βCDs in an aqueous environment. These findings strongly correlate with those reported for other hydrophobic ligands in complex with βCDs [47–49].

Several studies have shown that the methyl and hydroxypropyl modifications on βCD can significantly enhance the stability of many lipophilic guest molecules [50–52]. In good agreement with these reports, our results demonstrate that the ΔG_{bind, MM/GBSA} of MG in complex with modified βCDs is significantly lower than that of MG in complex with unsubstituted βCD, which can be ranked in the order of MG/βCD (−2.34 ± 0.35 kcal/mol) > MG/2HPβCD (−3.35 ± 0.14 kcal/mol, *) > MG/DMβCD.
Taken altogether, all structural and energetic analyses convince that DMβCD analog is the most suitable host for MG encapsulation.

| Energy Component (kcal/mol) | MG/βCD | MG/DMβCD | MG/2HPβCD |
|-----------------------------|--------|----------|-----------|
| ΔEvdW                      | −27.61 ± 1.19 | −29.19 ± 0.29 | −28.59 ± 0.64 |
| ΔEele                      | −11.79 ± 0.40 | −4.43 ± 0.19 | −6.40 ± 0.90 |
| ΔEMM                       | −39.40 ± 1.58 | −33.62 ± 0.26 | −34.99 ± 0.26 |
| ΔGsolv,polar               | 22.14 ± 0.91  | 12.72 ± 0.13  | 17.17 ± 0.54  |
| ΔGsolv,non-polar           | −2.83 ± 0.04  | −2.98 ± 0.01  | −3.10 ± 0.02  |
| ΔGele                      | 19.31 ± 0.86  | 9.73 ± 0.12   | 14.06 ± 0.57  |
| ΔGsolv,polar + ΔEele       | 10.35 ± 0.53  | 8.29 ± 0.19   | 10.77 ± 0.47  |
| ΔGsolv,non-polar + ΔEvdW   | −30.44 ± 1.24 | −32.18 ± 0.31 | −31.69 ± 0.66 |
| TΔS                        | −17.74 ± 0.36 | −18.16 ± 0.13 | −17.57 ± 0.42 |
| ΔGbonds, MM/GBSA           | −2.34 ± 0.35  | −5.73 ± 0.04  | −3.35 ± 0.14  |

3.5. Phase Solubility Study and Thermodynamic Parameters

As the molecular modeling results suggest that DMβCD derivative is the most preferential host for MG, we further confirmed our findings by conducting the experimental phase solubility study and Van’t Hoff-based thermodynamic parameter evaluation.

Phase solubility diagrams of all studied inclusion complexes at temperatures 30, 37, and 45 °C are summarized in Figure 5 and Table S1, where the corresponding Kc values are given in Table 2. The obtained results show that the increased βCD(s) concentrations can enhance the solubility of MG in a liner manner (ranked in the order of DMβCD >> 2HPβCD > βCD), indicating that the stoichiometric ratio between MG and βCD(s) is 1:1 (A1 type) [41]. By considering the stability of all studied inclusion complexes at 30 °C, the highest Kc value is detected in MG/DMβCD (2245 M⁻¹) followed by MG/HPβCD (684 M⁻¹) and MG/βCD (562 M⁻¹), respectively. Moreover, the solubility of MG is dramatically increased up to ~7 times, ~28 times, and ~10 times by complexation with βCD, DMβCD, and HPβCD, respectively (Table 4). These observations are consonant well with several reports demonstrating that βCD derivatives, especially DMβCD, could significantly enhance the stability and solubility of hydrophobic guest molecules better than natural βCD [25,53,54]. However, the increased temperature remarkably reduces the stability of all investigated complexes, in a manner similar to previous works [55,56].

Using Van’t Hoff plot (see Supporting Information, Figure S1), the obtained thermodynamic values, i.e., ΔH, ΔS, and ΔGbonds, exp, are summarized in Table 3. The negative ΔH (−20.77, −23.27, and −17.39 kcal/mol for MG/βCD, MG/DMβCD, and MG/HPβCD, respectively) suggests an exothermic process. Moreover, the formation of all inclusion complexes is spontaneous, as evidenced by the negative sign of ΔGbonds, exp values at 30 °C (−3.71, −4.56, −3.85 kcal/mol for MG/βCD, MG/DMβCD, and MG/HPβCD, respectively). Notably, the trend of MM/GBSA-based free energies strongly agrees with ΔGbonds, exp values, indicating that MM/GBSA serves as a suitable method for predicting the binding affinity of MG/βCDs inclusion complexes, which is in good agreement with several studies on other host-guest systems [56–60].

Taken together, based on theoretical and experimental investigations, we selected the MG/DMβCD, showing the highest stability, for further structural characterizations in comparison to the MG/βCD and the free form of MG.
An excess amount of MG was added to βCD(s) solutions (0–10 mM). The mixtures were shaken (250 rpm) at 30 °C, 37 °C, and 45 °C for 72 h. Subsequently, the suspensions were centrifuged at 12,000 rpm for 15 min. The amount of MG presenting in solution was measured by UV-Vis spectroscopy at 415 nm. Data are expressed as mean ± SEM of three independent experiments.

### Table 2. $K_c$ of MG/βCDs inclusion complexes at different temperatures. Note that the 95% confidence interval and the other statistic values for the slope and the y-intercept of linear regression are shown in Table S2.

| Temperature (°C) | Stability Constant ($K_c$, M$^{-1}$) |
|------------------|----------------------------------|
|                  | MG/βCD  | MG/DMβCD | MG/HPβCD |
| 30               | 562     | 2245     | 684      |
| 37               | 165     | 643      | 245      |
| 45               | 109     | 358      | 173      |

Table 3. Thermodynamic values for the inclusion complex formation of MG with βCDs derived from Van’t Hoff plots (using $R$ of $1.985 \times 10^{-3}$ kcal·mol$^{-1}$·K$^{-1}$ and $T$ of 303 K) in comparison to the $\Delta G_{bind, MM/GBSA}$. Note that the 95% confidence interval and the other statistic values for the slope and the y-intercept of linear regression are shown in Table S3.

| Thermodynamic Parameter (kcal/mol) | MG/βCD | MG/DMβCD | MG/HPβCD |
|-----------------------------------|--------|----------|----------|
| $\Delta H$                        | 20.77  | 23.27    | 17.39    |
| $\Delta T$                        | 17.06  | 18.71    | 13.54    |
| $\Delta G_{bind, exp}$ (30 °C)    | 3.71   | 4.56     | 3.85     |
| $\Delta G_{bind, MM/GBSA}$ (Table 1) | 2.34 ± 0.35 | 5.73 ± 0.04 | 3.35 ± 0.14 |

Table 4. Solubility of MG and its inclusion complexes at 30 °C.

| Solubility of MG (mg/L) |
|-------------------------|
| MG                      | 1.7 |
| MG/βCD                  | 11.5|
| MG/DMβCD                | 47.2|
| MG/HPβCD                | 17.1|
3.6. Inclusion Complex Characterization

3.6.1. Thermal Behavior of MG and Its Inclusion Complexes

The thermal behaviors of the starting materials (MG, βCD, and DMβCD) and the inclusion complexes (MG/βCD and MG/DMβCD) were characterized in the solid state by DSC analysis (Figure 6). The characteristic endothermic/exothermic peaks of the free compounds are as follows: MG at 208.7 °C and 213.0 °C, βCD at 118.9 °C, and DMβCD at 77.1 °C, 184.9 °C, and 293.9 °C. The broad endothermic peak of βCD detected at 118.9 °C corresponds to the release of water molecules from the hydrophobic cavity [61]. As shown in supplemental Figure S2, the distinct thermal peaks of the free MG were expressed in all the physical mixture products, indicating that the physical mixing method does not provide a real inclusion complex.

As a host-guest complexation process is occurred, the thermal features of the acquired product are dramatically changed [62]. In accordance with these facts, our data in Figure 6 reveal that the thermal peaks of the free MG were totally disappeared in all the freeze-dried inclusion complexes. In addition, in the case of MG/βCD inclusion complexation, the characteristic broad peak of βCD at 118.9 °C is shifted to 57.2 °C by the influence of the MG-induced water replacement. The similar change of dehydration peak of βCD after ligand complexation was also found by Rajendiran and coworkers [63]. Similarly, the broad endothermic peak (77.1 °C) and the exothermic peaks (184.9 °C and 293.9 °C) of DMβCD are dramatically shifted with a decreased intensity after complexing with MG, in good agreement with previous study [64]. Therefore, the freeze-drying method can successfully generate the new solid phase between MG and βCDs.

![Figure 6. DSC thermogram of MG, βCD, DMβCD, and the freeze-dried inclusion complexes (MG/βCD and MG/DMβCD). Note that prior to perform DSC, all compounds were dissolved in deionized water and were subsequently lyophilized for 3 days.](image-url)
3.6.2. Surface Morphological Changes upon Inclusion Complexation

It was evident that the inclusion complex formation dramatically induces the alterations of the particle shape and surface morphology of the resulting products [65–67]; thus, we performed SEM analysis in order to characterize the morphological changes upon host-guest encapsulation. The SEM micrographs at 300 times magnification of all investigated samples are summarized in Figure 7. In the case of the unbound forms, βCD and DMβCD are defined as rod-shaped structure, in accord with previous reports [68,69], whereas MG displays a flake-like feature. Upon molecular complexation, the surface morphology and the particle shape/size of the obtained freeze-dried inclusion complexes MG/βCD and MG/DMβCD (Figure 7D,E) are totally different from those of the free forms, confirming the successful formation between MG and βCDs.

![SEM images of inclusion complexes](image)

**Figure 7.** SEM images of (A) MG, (B) βCD, (C) DMβCD, (D) MG/βCD, and (E) MG/DMβCD at 300 times magnification.

3.7. Cytotoxicity of MG/βCDs Inclusion Complexes toward Lung Cancer

Lung cancer is the first leading cause of cancer-related death globally with its five-year survival rate of only 17.8% [70]. In this study, we evaluated the cytotoxic activity of MG and its inclusion complexes (MG/βCD, MG/DMβCD, and MG/HPβCD) against A549 human lung cancer cell line using MTT assay. The cell viability (% of control) results are summarized in Figure 8A, whereas the IC_{50} values (μM) are shown in Figure 8B. The obtained results reveal that MG, MG/βCD, MG/DMβCD, and MG/HPβCD decrease cell viability in a concentration-dependent manner, in which MG/HPβCD exhibits the lowest cell viability followed by MG/DMβCD, MG/βCD, and MG, respectively (Figure 8A).

Multiple lines of evidence have shown that βCD inclusion complexations can potentially enhance the antitumor activity of lipophilic guest compounds [25,67,71]. In correlation with these reports, the present study shows that the inclusion complexes of MG significantly increase the anticancer effect on A549 cells, which can be ranked in the order of MG/HPβCD (IC_{50} of 5.62 ± 0.40 μM, ***) > MG/DMβCD (IC_{50} of 13.45 ± 0.24 μM, ***) > MG/βCD (17.63 ± 0.42 μM, ***) >> MG (42.86 ± 2.09 μM) (Figure 8B). The enhancement of anticancer activity of MG by complexation with βCDs is likely due to the reason that βCDs can infiltrate into the drug permeation barrier, called unstirred water layer (UWL) consisting of a large number of strong H-bond networks [72], better than the free form of lipophilic MG. It is likely that the introduced hydrophilic HP (HPβCD) and the hydrophobic methyl groups on βCD (DMβCD) could respectively (i) enhance the flux of drug though UWL [73] and (ii) interact with biological membrane greater than unmodified CD [74]. Therefore, the cytotoxic effect on A549...
of MG/HPβCD and MG/DMβCD is higher than that of MG/βCD. Importantly, the free form of βCD, DMβCD, and HPβCD does not affect the antitumor property of MG/βCDs inclusion complexes, as evidenced by the cell viability values of >90% (Figure 8C).

**Figure 8.** (A) Cell viability of A549 human lung cell line after treatment with logarithmic concentrations (1, 3, 10, 30, and 100 µM) of MG, MG/βCD, MG/DMβCD, and MG/HPβCD for 48 h. (B) The IC₅₀ (µM) of all investigated compounds. (C) Cell viability of A549 cells treated with the free form of βCD, DMβCD, and HPβCD. Data are expressed as mean ± SEM of three independent experiments. ***p ≤ 0.001 vs. MG.

4. Conclusions

In the present study, we combined theoretical and experimental studies to identify the most suitable βCD host molecule for MG, a promising anticancer agent extracted from *Mansonia gagei*, for improving the aqueous solubility and the antitumor potential. The 90-ns MD simulations in triplicate revealed that MG preferentially positioned inside βCD, DMβCD, and 2HPβCD cavities through its aromatic ring. The MG binding led to the rigidity of βCDs by increasing the intramolecular H-bond formations on the wider rim. Among the three different MG/βCDs, the ΔG_bind values from MM/GBSA calculations and experimental phase solubility study revealed that MG/DMβCD was the most stable complex, as supported by the lowest water accessibility toward MG atomic radii and the highest number of contacts between host and guest molecules. The successful formation of MG/βCDs was confirmed by DSC and SEM techniques. The anticancer activity of MG toward A549 lung cancer cells was significantly enhanced (~2–7 fold) by complexation with βCDs, especially HPβCD and DMβCD analogs. Altogether, the obtained results confirmed the working hypothesis and demonstrated the good potentiality of βCD derivatives as suitable formulations of MG for further pharmaceutical and medicinal applications.

Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/9/10/545/s1, Figure S1: Van’t Hoff plots of MG/βCDs inclusion complexes, Figure S2: DSC thermogram of MG, βCD, DMβCD, and the physical mixtures MG/βCD and MG/DMβCD. Note that prior to perform DSC, all compounds were not dissolved in deionized water and were not subsequently lyophilized., Table S1: Linear equation of MG/βCDs inclusion complexes at different temperatures derived from Figure S5., Table S2: The 95% confidence interval and the other statistic values for the slope and the y-intercept of linear regression of phase solubility study derived from Figure S5., Table S3: The 95% confidence interval and the other statistic values for the slope and the y-intercept of linear regression of Van’t Hoff plot derived from Figure S1.
Author Contributions: P.M. and T.R.; conceptualization. P.M. conducted theoretical and experimental studies. T.C. and P.W.; methodology. M.P. and P.W.; resources. W.C. purified, synthesized, and identified MG using NMR. P.M., T.R., P.W., and T.C. analyzed the data. P.M. wrote the original manuscript. All authors reviewed and edited the manuscript. T.R.; funding acquisition.

Funding: This research was funded by the Thailand Research Fund (grant number RSA6280085). P.M. thanks the Science Achievement Scholarship of Thailand for Ph.D. scholarship, the 90th Anniversary of Chulalongkorn University Fund (Ratchadaphiseksomphot Endowment Fund), and the Overseas Presentations of Graduate Level Academic Thesis from Graduate School. The Chulalongkorn Academic Advancement into its 2nd Century Project (Project [CUAASC] and Chulalongkorn University’s Ratchadapisek Sompot Fund [grant number GCURP59022301]) are acknowledged for computing resources.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Nagai, H.; Kim, Y.H. Cancer prevention from the perspective of global cancer burden patterns. J. Thorac. Dis. 2017, 9, 448–451. [CrossRef] [PubMed]
2. Pardee, A.B.; Li, Y.Z.; Li, C.J. Cancer therapy with beta-lapachone. Curr. Cancer Drug Targets 2002, 2, 227–242. [CrossRef] [PubMed]
3. Aziz, M.H.; Dreckschmidt, N.E.; Verma, A.K. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res. 2008, 68, 9024–9032. [CrossRef] [PubMed]
4. Hou, Y.; Xu, J.; Liu, X.; Xia, X.; Li, N.; Bi, X. Shikonin induces apoptosis in the human gastric cancer cells HGC-27 through mitochondria-mediated pathway. Pharmacogn. Mag. 2015, 11, 250–256. [CrossRef] [PubMed]
5. Baghdadi, M.A.; Al-Abbasi, F.A.; El-Halawany, A.M.; Aseeri, A.H.; Al-Abd, A.M. Anticancer Profiling for Coumarins and Related O-Naphthoquinones from Mansonia gagei against Solid Tumor Cells In Vitro. Molecules 2018, 23, 1020. [CrossRef] [PubMed]
6. Wang, D.; Xia, M.; Cui, Z.; Tashiro, S.-I.; Onodera, S.; Ikejima, T. Cytotoxic effects of mansonone E and F isolated from Ulmus pumila. Biol. Pharm. Bull. 2004, 27, 1025–1030. [CrossRef]
7. Liu, Z.; Huang, S.-L.; Li, M.-M.; Huang, Z.-S.; Lee, K.S.; Gu, L.-Q. Inhibition of thioredoxin reductase by mansonone F analogues: Implications for anticancer activity. Chem. Interactions 2009, 177, 48–57. [CrossRef]
8. Johnson, J.; Gandhidasan, I.; Murugesan, R. Cytotoxicity and superoxide anion generation by some naturally occurring quinones. Free. Radic. Boil. Med. 1999, 26, 1072–1078. [CrossRef]
9. Wu, W.-B.; Ou, J.-B.; Huang, Z.-H.; Chen, S.-B.; Ou, T.-M.; Tan, J.-H.; Li, D.; Shen, L.-L.; Huang, S.-L.; Gu, L.-Q.; et al. Synthesis and evaluation of mansonone F derivatives as topoisomerase inhibitors. Eur. J. Med. Chem. 2011, 46, 3339–3347. [CrossRef]
10. Tanaka, N.; Yasue, M.; Imamura, H. The quinonoid pigments of mansonia altissima wood. Tetrahedron Lett. 1966, 7, 2767–2773. [CrossRef]
11. Hairani, R.; Mongkol, R.; Chavasiri, W. Allyl and prenyl ethers of mansonone G, new potential semisynthetic antibacterial agents. Bioorganic Med. Chem. Lett. 2016, 26, 5500–5503. [CrossRef] [PubMed]
12. Aljohani, H.G.; Hegazy, G.A.; AlAmoudi, A.A.; Agabnoor, G.M.; El-Halawany, A.M.; Al-Abd, A.M. Abstract LB-073: Mansonone-G is more potent antiproliferative against liver cancer cells than its coumarin derivative (mansorin-A) despite their antagonistic interaction with 5-fluorouracil. Cancer Chem. 2018, 78. [CrossRef]
13. Dai, Y.; Harinantenaina, L.; Brodie, P.J.; Callmander, M.W.; Randrianasolo, S.; Rakotobe, E.; Rasamison, V.E.; Kingston, D.G.I. Isolation and synthesis of two antiproliferative calamene-type sesquiterpenoids from Sterculia tavia from the Madagascar rain forest. Bioorganic Med. Chem. 2012, 20, 6940–6944. [CrossRef] [PubMed]
14. Mahalapbutr, P.; Wonganan, P.; Chavasiri, W.; Rungrotmongkol, T. Butoxy Mansonone G Inhibits STAT3 and Akt Signaling Pathways in Non-Small Cell Lung Cancers: Combined Experimental and Theoretical Investigations. Cancers 2019, 11, 437. [CrossRef] [PubMed]
15. Szejtli, J. Introduction and General Overview of Cyclodextrin Chemistry. Chem. Rev. 1998, 98, 1743–1754. [CrossRef] [PubMed]
16. De Carvalho, L.B.; Burusco, K.K.; Jaime, C.; Venâncio, T.; De Carvalho, A.F.S.; Murgas, L.D.S.; Pinto, L.D.M.A.; Burusco-Goni, K.K. Complexes between methylene blue and β-cyclodextrin for application in aquaculture production. Carbohydr. Polym. 2018, 179, 386–393. [CrossRef] [PubMed]

17. Tommasini, S.; Raneri, D.; Ficarra, R.; Calabrò, M.L.; Stancaneli, R.; Ficarra, P. Improvement in solubility and dissolution rate of flavonoids by complexation with β-cyclodextrin. J. Pharm. Biomed. Anal. 2004, 35, 379–387. [CrossRef]

18. Veiga, M.D.; Díaz, P.J.; Ahsan, F. Interactions of Griseofulvin with Cyclodextrins in Solid Binary Systems. J. Pharm. Sci. 1998, 87, 891–900. [CrossRef]

19. Del Valle, E.M.M. Cyclodextrins and their uses: A review. Process Biochem. 2004, 39, 1033–1046. [CrossRef]

20. Vaidya, B.; Shukla, S.K.; Kolluru, S.; Huen, M.; Mulla, N.; Kanabar, D.; Palakurthi, S.; Ayehunie, S.; De Carvalho, L.B.; Burusco, K.K.; Jaime, C.; Venâncio, T. Enhancement of solubility and bioavailability of ropivacaine via hydroxypropyl-β-cyclodextrin encapsulation. Pharm. Biol. 2016, 54, 130–138. [CrossRef] [PubMed]

21. Loftsson, T.; Másson, M. Cyclodextrins in topical drug formulations: theory and practice. Int. J. Pharm. 2001, 225, 15–30. [CrossRef]

22. de Araujo, D.R.; Tsuneda, S.S.; Cereda, C.M.S.; Del, G.F.; Carvalho, F.; Preté, P.S.C.; Fernandes, S.A.; Yokaichiya, F.; Franco, M.K.K.D.; Mazzaro, I.; et al. Development and pharmacological evaluation of ropivacaine-2-hydroxypropyl-β-cyclodextrin inclusion complex. Eur. J. Pharm. Sci. 2008, 33, 60–71. [CrossRef] [PubMed]

23. Kikuchi, M.; Uekama, K. E 1-Hexylcarbamoyl-5-fluorouracil (HCFU). Yakugaku Zasshi 2017, 91, 96–104. [CrossRef] [PubMed]

24. Kai-Hang, L.; Mengying, S.; Guping, T.; Xiurong, H.U. [Preparation, characterization and antitumor of κ-cyclodextrin inclusion of an anti-cancer drug regorafenib]. Zhejiang da xue xue bao. Yi xue ban = Zhejiang University J. Med Sci. 2017, 46, 151–159.

25. Kikuchi, M.; Uekama, K. Effect of Dimethyl β-Cyclodextrin on Oral or Rectal Absorption of 1-Hexylcarbamoyl-5-fluorouracil (HCFU). Yakugaku Zasshi 1988, 108, 156–163. [CrossRef] [PubMed]

26. Kicuntod, J.; Sangpheak, K.; Mueller, M.; Wolschann, P.; Viennstein, H.; Yanaka, S.; Kato, K.; Chavasiri, W.; Pongsawasdi, P.; Khuntawee, W.; Wolschann, P.; et al. Theoretical and Experimental Studies on Inclusion Complexes of Pinostrobin and beta-Cyclodextrins. Sci. Pharm. 2018, 86, 5. [CrossRef] [PubMed]

27. Ramos, A.I.; Vaz, P.D.; Braga, S.S.; Silva, A.M.S. Association of aescin with β- and γ-cyclodextrins studied by DFT calculations and spectroscopic methods. Beilstein J. Nanotechnol. 2017, 8, 348–357. [CrossRef] [PubMed]

28. Aree, T.; Jongrungruangchok, S. Structure-antioxidant activity relationship of beta-cyclodextrin inclusion of an anti-cancer drug regorafenib]. Zhejiang da xue xue bao. Yi xue ban = Zhejiang University J. Med Sci. 2017, 46, 151–159.

29. Mahalapbutr, P.; Chusuth, P.; Kungwan, N.; et al. Theoretical and Experimental Studies on Inclusion Complexes of Pinoctromb (β-Cyclodextrin) with Various Cyclodextrins. Sci. Pharm. 2015, 83, 15–30. [CrossRef] [PubMed]

30. Mahalapbutr, P.; Chusuth, P.; Kungwan, N.; et al. Theoretical and Experimental Studies on Inclusion Complexes of Pinoctromb (β-Cyclodextrin) with Various Cyclodextrins. Sci. Pharm. 2015, 83, 15–30. [CrossRef] [PubMed]

31. Mahalapbutr, P.; Chusuth, P.; Kungwan, N.; et al. Theoretical and Experimental Studies on Inclusion Complexes of Pinoctromb (β-Cyclodextrin) with Various Cyclodextrins. Sci. Pharm. 2015, 83, 15–30. [CrossRef] [PubMed]

32. Mahalapbutr, P.; Chusuth, P.; Kungwan, N.; et al. Theoretical and Experimental Studies on Inclusion Complexes of Pinoctromb (β-Cyclodextrin) with Various Cyclodextrins. Sci. Pharm. 2015, 83, 15–30. [CrossRef] [PubMed]

33. Hanpaibool, C.; Chakchoaromsap, T.; Arifin; Hijikata, Y.; Irie, S.; Wolschann, P.; Kungwan, N.; Pongsawasdi, P.; Ounjai, P.; Rungrotmongkol, T. Theoretical analysis of orientations and tautomerization of genistein in β-cyclodextrin. J. Mol. Liq. 2018, 265, 16–23. [CrossRef]

34. Mahalapbutr, P.; Thitinanthavet, K.; Kedkham, T.; Nguyen, H.; Theu, L.T.H.; Dokmaisrijan, S.; Huynh, L.; Kungwan, N.; Rungrotmongkol, T. A theoretical study on the molecular encapsulation of luteolin and pinocembrin with various derivatized beta-cyclodextrins. J. Mol. Struct. 2019, 1180, 480–490. [CrossRef]
35. Mahalapbutr, P.; Darai, N.; Panman, W.; Opasmahakul, A.; Kungwan, N.; Hannongbua, S.; Rungrotmongkol, T. Atomicistic mechanisms underlying the activation of the G protein-coupled sweet receptor heterodimer by sugar alcohol recognition. Sci. Rep. 2019, 9, 10205. [CrossRef]
36. Kirschner, K.N.; Yongye, A.B.; Tschampel, S.M.; Gonzalez-Outeirino, J.; Daniels, C.R.; Foley, B.L.; Woods, R.J. GLYCAM06: A generalizable biomolecular force field. Carbohydrates. J. Comput. Chem. 2008, 29, 622–655. [CrossRef]
37. Wang, J.; Wolf, R.M.; Caldwell, J.W.; Kollman, P.A.; Case, D.A. Development and testing of a general amber force field. J. Comput. Chem. 2004, 25, 1157–1174. [CrossRef] [PubMed]
38. Ryckaert, J.-P.; Ciccotti, G.; Berendsen, H.J. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 1977, 23, 327–341. [CrossRef]
39. Luty, B.A.; Van Gunsteren, W.F. Calculating Electrostatic Interactions Using the Particle–Particle Particle–Mesh Method with Nonperiodic Long-Range Interactions. J. Phys. Chem. 1996, 100, 2581–2587. [CrossRef]
40. Genheden, S.; Ryde, U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin. Drug Discov. 2015, 10, 499–511. [CrossRef]
41. Higuchi, T. A phase solubility technique. Adv. Anal. Chem. Instrum. 1965, 4, 117–211.
42. Mahalapbutr, P.; Nutho, B.; Wolschann, P.; Chavasiri, W.; Kungwan, N.; Rungrotmongkol, T. Molecular insights into inclusion complexes of mannosone E and H enantiomers with various beta-cyclodextrins. J. Mol. Graph. Model. 2018, 79, 72–80. [CrossRef] [PubMed]
43. Yang, L.J.; Ma, S.X.; Zhou, S.Y.; Chen, W.; Yuan, M.W.; Yin, Y.Q.; Yang, X.D. Preparation and characterization of inclusion complexes of naringenin with beta-cyclodextrin or its derivative. Carbohydr. Polym. 2013, 98, 861–869. [CrossRef] [PubMed]
44. Wongpituk, P.; Nutho, B.; Panman, W.; Kungwan, N.; Wolschann, P.; Rungrotmongkol, T.; Nunthaboot, N. Structural dynamics and binding free energy of neral-cyclodextrins inclusion complexes: molecular dynamics simulation. Mol. Simul. 2017, 43, 1356–1363. [CrossRef]
45. Ren, B.; Gao, H.; Cao, Y.; Jia, L. In Silico understanding of the cyclodextrin–phenanthrene hybrid assemblies in both aqueous medium and bacterial membranes. J. Hazard. Mater. 2015, 285, 148–156. [CrossRef] [PubMed]
46. Mongan, J.; Simmerling, C.; McCammon, J.A.; Case, D.A.; Onufriev, A. Generalized Born model with a simple, robust molecular volume correction. J. Chem. Theory Comput. 2007, 3, 156–169. [CrossRef] [PubMed]
47. Chen, W.; Chang, C.-E.; Gilson, M.K. Calculation of Cyclodextrin Binding Affinities: Energy, Entropy, and Implications for Drug Design. Biophys. J. 2004, 87, 3035–3049. [CrossRef] [PubMed]
48. Ferruglia, M.; Ferrone, M.; Lodi, A.; Pricl, S. Host–guest inclusion complexes between anticancer drugs and beta-cyclodextrin: computational studies. Carbohydr. Polym. 2003, 53, 15–44. [CrossRef]
49. Liu, L.; Guo, Q.-X. The Driving Forces in the Inclusion Complexation of Cyclodextrins. J. Incl. Phenom. Macrocycl. Chem. 2002, 42, 1–14. [CrossRef]
50. Jullian, C.; Cifuentes, C.; Alfaro, M.; Miranda, S.; Barriga, G.; Olea-Azar, C. Spectroscopic characterization of the inclusion complexes of luteolin with native and derivatized beta-cyclodextrin. Carbohydr. Polym. 2010, 82, 1505–1513. [CrossRef]
51. Wang, D.W.; Ouyang, C.B.; Liu, Q.; Yuan, H.L.; Liu, X.H. Inclusion of quinestrol and nitrazepam stability. J. de Pharm. de Belg. 1993, 48, 383–388.
56. Sangpheak, W.; Kicuntod, J.; Schuster, R.; Rungrotmongkol, T.; Wolschann, P.; Kungwan, N.; Viernstein, H.; Mueller, M.; Pongsawasdi, P. Physical properties and biological activities of hesperetin and naringenin in complex with methylated beta-cyclodextrin. *Beilstein J. Org. Chem.* **2015**, *11*, 2763–2773. [CrossRef]

57. Rungrotmongkol, T.; Chakcharoensap, T.; Pongsawasdi, P.; Kungwan, N.; Wolschann, P. The inclusion complexation of daidzein with beta-cyclodextrin and 2,6-dimethyl-beta-cyclodextrin: a theoretical and experimental study. *Mon. für Chem.* - *Chem. Mon.* **2018**, *149*, 1739–1747. [CrossRef]

58. Suarez, D.; Diaz, N. Affinity Calculations of Cyclodextrin Host-Guest Complexes: Assessment of Strengths and Weaknesses of End-Point Free Energy Methods. *J. Chem. Inf. Modeling* **2019**, *59*, 421–440. [CrossRef]

59. Genheden, S. MM/GBSA and LIE estimates of host-guest affinities: Dependence on charges and solvation model. *J. Comput. Mol. Des.* **2011**, *25*, 1085–1093. [CrossRef]

60. Suwandecha, T.; Rungrum, C.; Namuangruk, S.; Ruktanonchai, U.; Sawatdee, S.; Dechraksa, J.; Srichana, T. Host-guest interactions between sildenafil and cyclodextrins: Spectrofluorometric study and molecular dynamic modeling. *J. Mol. Graph. Model.* **2017**, *77*, 115–120. [CrossRef]

61. Hadžarugă, N.G.; Hadžarugă, D.I.; Paunescu, V.; Tatu, C.; Ordovi, V.L.; Bandur, G.; Lupea, A.X. Thermal stability of the linoleic acid/alpha- and beta-cyclodextrin complexes. *Food Chem.* **2006**, *99*, 500–508. [CrossRef]

62. Abarca, R.L.; Rodriguez, F.J.; Guarda, A.; Galotto, M.J.; Bruna, J.E. Characterization of beta-cyclodextrin inclusion complexes containing an essential oil component. *Food Chem.* **2016**, *196*, 968–975. [CrossRef] [PubMed]

63. Rajendiran, N.; Siva, S. Inclusion complex of sulfadimethoxine with cyclodextrins: Preparation and characterization. *Carbohydr. Polym.* **2014**, *101*, 828–836. [CrossRef] [PubMed]

64. Ventura, C.A.; Giannone, I.; Paolino, D.; Pistara, V.; Corsaro, A.; Puglisi, G. Preparation of celecoxib-dimethyl-beta-cyclodextrin inclusion complex: Characterization and in vitro permeation study. *Eur. J. Med. Chem.* **2005**, *40*, 624–631. [CrossRef] [PubMed]

65. Rakmai, J.; Cheirislip, B.; Mejuto, J.C.; Simal-Gándara, J.; Torrado-Agrasar, A. Antioxidant and antimicrobial properties of encapsulated guava leaf oil in hydroxypropyl-beta-cyclodextrin. *Ind. Crops Prod.* **2018**, *111*, 219–225. [CrossRef]

66. Zarif, M.S.; Afidah, A.R.; Abdullah, J.M.; Shariza, A.R. Physicochemical characterization of vancomycin and its complexes with beta-cyclodextrin. *Biomed. Res. (In India)* **2012**, *23*, 513–520.

67. Yallapu, M.M.; Jaggi, M.; Chauhan, S.C. beta-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells. *Colloids Surf. B: Biointerfaces* **2010**, *79*, 113–125. [CrossRef]

68. Rajbanshi, B.; Saha, S.; Das, K.; Barman, B.K.; Sengupta, S.; Bhattacharjee, A.; Roy, M.N. Study to Probe Subsistence of Host-Guest Inclusion Complexes of alpha and beta-Cyclodextrins with Biologically Potent Drugs for Safety Regulatory Dischargement. *Sci. Rep.* **2018**, *8*, 13031. [CrossRef]

69. Gil Choi, S.; Lee, S.-E.; Kang, B.-S.; Ng, C.L.; Davaa, E.; Park, J.-S. Thermosensitive and Mucoadhesive Sol-Gel Composites of Paclitaxel/Dimethyl-beta-Cyclodextrin for Buccal Delivery. *PLOS ONE* **2014**, *9*, e109090.

70. Wong, M.C.S.; Lao, X.Q.; Ho, K.-F.; Goggins, W.B.; Tse, S.L.A. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. *Sci. Rep.* **2017**, *7*, 14300. [CrossRef]

71. Wang, F.; Yang, B.; Zhao, Y.; Liao, X.; Gao, C.; Jiang, R.; Han, B.; Yang, J.; Liu, M.; Zhou, R. Host-guest inclusion system of scutellarein with 2-hydroxypropyl-beta-cyclodextrin: preparation, characterization, and anticancer activity. *J. Biomater. Sci. Polym. Ed.* **2014**, *25*, 594–607. [CrossRef] [PubMed]

72. Loftsson, T. Drug permeation through biomembranes: cyclodextrins and the unstirred water layer. *Die Pharm.* **2012**, *67*, 363–370.

73. Brewster, M.E.; Noppe, M.; Peeters, J.; Loftsson, T. Effect of the unstirred water layer on permeability enhancement by hydropilic cyclodextrins. *Int. J. Pharm.* **2007**, *342*, 250–253. [CrossRef] [PubMed]

74. Nishijo, J.; Shiota, S.; Mazima, K.; Inoue, Y.; Mizuno, H.; Yoshida, J. Interactions of Cyclodextrins with Dipalmitoyl, Distearoyl, and Dimyristoyl Phosphatidyl Choline Liposomes. A Study by Leakage of Carboxyfluorescein in Inner Aqueous Phase of Unilamellar Liposomes. *Chem. Pharm. Bull.* **2000**, *48*, 48–52. [CrossRef]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).